Simon Clark
Professor University Of Reading
Seminars
Tuesday 2nd December 2025
The Complement Advisory Board Fireside Chat: An Overview of the Complement Therapeutics Landscape
9:00 am
- Discussing the dynamic landscape of complement drug development, exploring novel targets and diverse therapeutic modalities and their potential across various diseases, including kidney, CNS, and ophthalmology
- Addressing critical operational and clinical challenges in complement therapy, delivery, and oral formulations
- Focussing on the scientific and translational hurdles that remain, covering the importance of developing robust biomarkers, predictive models the promising role of complement inhibitors in combination therapies
Tuesday 2nd December 2025
The Complement Advisory Board Fireside Chat: An Overview of the Complement Therapeutics Landscape
9:00 am
- Discussing the dynamic landscape of complement drug development, exploring novel targets and diverse therapeutic modalities and their potential across various diseases, including kidney, CNS, and ophthalmology
- Addressing critical operational and clinical challenges in complement therapy, delivery, and oral formulations
- Focussing on the scientific and translational hurdles that remain, covering the importance of developing robust biomarkers, predictive models the promising role of complement inhibitors in combination therapies
Monday 1st December 2025
Rethinking the Delivery of Complement-Based Therapeutics to Ensure Complement Moderators are Reaching the Correct Targets in the Appropriate Quantities
2:30 pm
Join this workshop to deepen your understanding of the approaches being used to overcome the challenges in effectively delivering complement mediators to their target tissues and discuss optimal dosages for complement-based therapeutics for different organs.
- Understanding organ-specific differences and their implications for developing effective complement targeted therapies from a drug delivery perspective
- Exploring alternatives to traditional delivery methods such as ocular injection and addressing the unique architecture and environment of the eye when designing delivery methods.
- Debating the optimal uses for systemic vs local complement targeting considering the potential for broad immune suppression
- Examining the rationale for, and challenges of selectively modulating complement activity at the local site of disease given the organ-specific nature of complement-mediated diseases
- Reviewing innovative methods to concentrate complement inhibitors at the target organ or tissue, e.g. podocytes in C3G
- Discussing technologies and modalities that improve targeted delivery such as novel modalities like gene therapies, siRNA and small molecules for maximum therapeutic effect whilst reducing the systemic side effects associated with broadly acting complement inhibitors
- Assessing trade-offs between oral, IV and localized injection in achieving sitespecific targeting to enhance efficacy and mitigate systemic ‘black box’ warnings whilst considering patient experience and adherence
